Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has concluded a successful non-brokered private placement offering, issuing 4,167,778 units at C$0.18, totaling approximately $750,200.
Each unit comprises one share and one warrant exercisable at $0.25 per share within five years.
The proceeds will advance Phase II Non-Muscle Invasive Bladder Cancer clinical study, preclinical research of Rutherrin, and support general corporate needs.